Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Letai

Showing results (121-130 of 182) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2022
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene ExpressionMatthew L Hemming, Patrick Bhola, Michael A Loycano, et al.
The EMBO Journal|April 19, 2012
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1αDiego A Rodriguez, Sebastian Zamorano, Fernanda Lisbona, et al.
Blood Advances|October 26, 2020
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesHanna Scholze, Regan E Stephenson, Raymond Reynolds, et al.
BMC Gastroenterology|June 24, 2018
Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapyR Taylor Ripley, Deborah R Surman, Laurence P Diggs, et al.
Cancer Discovery|December 18, 2016
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to VenetoclaxJoan Montero, Jason Stephansky, Tianyu Cai, et al.
Science Translational Medicine|June 5, 2024
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimeticsFelix Korell, Michael L Olson, Diego Salas-Benito, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Leukemia|July 31, 2025
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphomaTayla B Heavican-Foral, Felix Korell, Irene Scarfò, et al.
Haematologica|May 27, 2014
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantationKazuyuki Murase, Haesook T Kim, O R Gregory Bascug, et al.
Science Signaling|June 18, 2020
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumorsPatrick D Bhola, Eman Ahmed, Jennifer L Guerriero, et al.
Pageof 19

Showing results (121-130 of 182) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2022
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene ExpressionMatthew L Hemming, Patrick Bhola, Michael A Loycano, et al.
The EMBO Journal|April 19, 2012
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1αDiego A Rodriguez, Sebastian Zamorano, Fernanda Lisbona, et al.
Blood Advances|October 26, 2020
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypesHanna Scholze, Regan E Stephenson, Raymond Reynolds, et al.
BMC Gastroenterology|June 24, 2018
Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapyR Taylor Ripley, Deborah R Surman, Laurence P Diggs, et al.
Cancer Discovery|December 18, 2016
Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to VenetoclaxJoan Montero, Jason Stephansky, Tianyu Cai, et al.
Science Translational Medicine|June 5, 2024
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimeticsFelix Korell, Michael L Olson, Diego Salas-Benito, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Leukemia|July 31, 2025
Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphomaTayla B Heavican-Foral, Felix Korell, Irene Scarfò, et al.
Haematologica|May 27, 2014
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantationKazuyuki Murase, Haesook T Kim, O R Gregory Bascug, et al.
Science Signaling|June 18, 2020
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumorsPatrick D Bhola, Eman Ahmed, Jennifer L Guerriero, et al.
Pageof 19